Small Cell Lung Cancer Drug Market And Pipeline 2020

By Author: bhardwaj
Total Articles: 19
Comment this article

small cell lung cancer drug market
DelveInsight’s Small Cell Lung Cancer Drug Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the SCLC, historical and forecasted epidemiology as well as the small cell lung cancer market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.

The small cell lung cancer market report provides current treatment practices, emerging drugs, SCLC market share of the individual therapies, current and forecasted SCLC market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current SCLC treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2017-2030

Small Cell Lung Cancer Disease Understanding and Treatment Algorithm
Lung cancer mainly begins in the lungs, and it may spread to lymph nodes or other ...
... organs in the body, such as the brain. However, cancer from other organs may also spread to the lungs. When cancer cells spread from one organ to another, they are called metastases. There are mainly two types of lung cancer small cell lung cancer and non-small cell lung cancer (NSCLC, the more common). The treatment method is different for both types.

SCLC spreads (metastasizes) much faster than NSCLC to other organs, whereas microscopically, small cell lung cancer is composed of much smaller cells. SCLC can be fatal in a few weeks if untreated, in contrast to most cases of NSCLC. Also, NSCLC accounts for about 80–85% of lung cancers.

small cell lung cancer is an aggressive disease with distinct pathological, clinical, and molecular characteristics along with having a high metastatic potential that results in clinically poor prognosis, which is not the case for NSCLC. SCLC is also known as ‘oat-cell’ cancer because the cells look like oats under the microscope. It often starts in the bronchi, then quickly grows and spread to other parts of the body, including the lymph nodes. This type of lung cancer represents about 15% of lung cancers and is typically caused by tobacco smoking. SCLC tends to spread quite early and it can also be classed as neuroendocrine tumors.

Diagnosis

The diagnosis of cancer mainly starts with a different set of tests that can be performed to examine cancer or for its better and effective treatment. They may start off by examining the extent of cancer metastasis, which can be done by analyzing what other parts of the body are affected apart from the point of initiation. For example, imaging tests—that displays the internal picture of the body—can indicate if cancer has spread, but they can never be used alone to diagnose small cell lung cancer.

A biopsy is recommended as it the only way for the doctor to confirm the presence of cancer; however, there are other methods also, if biopsy cannot be performed.

The doctor may consider these factors when choosing a diagnostic test:

Size, location, and type of cancer suspected
Signs and symptoms
Age and general health
The results of earlier medical tests
Treatment

It covers the details of conventional and current medical therapies available in the Small Cell Lung Cancer market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithm across the United States, Europe and Japan.

The DelveInsight Small Cell Lung Cancer market report gives a thorough understanding of Small Cell Lung Cancer by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Small Cell Lung Cancer treatment algorithms and treatment guidelines for Small Cell Lung Cancer in the US, Europe, and Japan.

Small Cell Lung Cancer Epidemiology
The Small Cell Lung Cancer epidemiology division provide insights about historical and current Small Cell Lung Cancer patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total incident cases of small cell lung cancer patients were found to be more in males than in females in 7MM during the study period i.e. 2017–2030.

The disease epidemiology covered in the report provides historical as well as forecasted Small Cell Lung Cancer epidemiology [segmented as Total Incident Patient Population, Gender-specific Incident Patient Population, Age-specific Incident Patient Population, Stage-Specific Incident Population, and Line-wise Treatment of Extensive-Stage SCLC] scenario of Small Cell Lung Cancer in 7MM covering United States, EU5 countries (Germany, France, Italy , Spain, and United Kingdom), and Japan from 2017 to 2030.

Country Wise- Small Cell Lung Cancer Epidemiology

The epidemiology segment also provides the Small Cell Lung Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Small Cell Lung Cancer Drug Chapters
Drug chapter segment of the Small Cell Lung Cancer report encloses the detailed analysis of Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Small Cell Lung Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

Opdivo (Nivolumab): Bristol-Myers Squibb

Opdivo (Nivolumab) by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. It is a prescription medicine used to treat people with unresectable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC), small cell lung cancer, advanced renal cell carcinoma, classical hodgkin lymphoma, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer and hepatocellular carcinoma. It is not known if Opdivo is safe and effective in children younger than 18 years of age. This drug is approved under accelerated approval based on overall response rate and duration of response for patients with metastatic small cell lung cancer with progression after platinum-based chemotherapy and at least one other line of therapy. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Keytruda (Pembrolizumab): Merck

Keytruda, also known as pembrolizumab, is a programmed death receptor-1 (PD-1)-blocking antibody. It is mainly used for cancers that are advanced, have spread to other parts of the body (metastatic) or are not responding to other treatments. In some cancers, it is only given to patients whose tumors produce high levels of a protein known as PD-L1. This drug is also used to help prevent the cancer from coming back after patients had surgery to remove melanoma (adjuvant therapy).

Small Cell Lung Cancer Emerging Drugs

Imfinzi +/- tremelimumab: AstraZeneca

Imfinzi (Durvalumab) also known as medi4736 with or without tremelimumab, is under development by AstraZeneca. It is administered intravenously after completing a combination of chemotherapy and radiation therapy (CRT) given at the same time, also known as concurrent CRT. Imfinzi may also attack healthy cells. It binds to a protein called PD-L1, which is found on some cancer cells and may block this protein and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor.

Lurbinectedin (PM01183): PharmaMar

Lurbinectedin (Zepsyre, PM1183) by PharmaMar, is a compound in clinical research that belongs to the RNA polymerase II enzyme inhibitors family, which is essential for the transcription process. By inhibiting transcription, the compound reduces the expression of certain factors that are involved in tumor progression and blocks the DNA repair system called NER. This eventually induces the death of tumor cells. The antitumor efficacy of PM1183 (lurbinectedin) is being investigated in several types of tumors. Currently it is in phase III clinical developmental trial for small cell lung cancer.

RRx-001: EpicentRx

EpicentRx is developing its lead program RRx-001, which is among a portfolio of immunotherapeutic compounds that normalize the tumor microenvironment, activate the tumor associated macrophages (TAMs) of the innate immune system, and sensitize solid tumors to standard therapies in small cell lung cancer, glioblastoma, colorectal cancer and additional cancers. It is a next generation, small molecule anticancer immunotherapeutic that down regulates the CD47/SIRPα axis and repolarizes TAMs and other immunosuppressive cells in the tumor microenvironment to an immunostimulatory phenotype. RRx-001 is designed to be used either as a monotherapy or in combination with chemotherapy, radiation therapy or immunotherapy. It has been granted Orphan Drug Designation from the US FDA and EMA for the treatment of patients with small cell lung cancer.

Small Cell Lung Cancer Market Outlook
The Small Cell Lung Cancer market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Small Cell Lung Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of Small Cell Lung Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Small Cell Lung Cancer market in the 7MM is expected to change in the study period 2017–2030. The therapeutic market of Small Cell Lung Cancer in seven major markets is expected to generate USD 444 million in 2017 and will increase in the study period 2017–2030.

Key Findings

This section includes a glimpse of the Small Cell Lung Cancer market in 7MM.

The United States Market Outlook

This section provides the total Small Cell Lung Cancer market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Small Cell Lung Cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Small Cell Lung Cancer market size and market size by therapies in Japan is also mentioned.

Small Cell Lung Cancer Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Small Cell Lung Cancer market or expected to get launched in the market during the study period 2017-2030. The analysis covers Small Cell Lung Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of Small Cell Lung Cancer market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Small Cell Lung Cancer Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Small Cell Lung Cancer key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Small Cell Lung Cancer emerging therapies.

Reimbursement Scenario in Small Cell Lung Cancer
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views
To keep up with current market trends, we take KOLs and SME's opinion working in Small Cell Lung Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Small Cell Lung Cancer market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Small Cell Lung Cancer Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

https://www.delveinsight.com/report-store/small-cell-lung-cancer-market